{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T10:24:03Z","timestamp":1785234243991,"version":"3.55.0"},"reference-count":103,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["CA15135"],"award-info":[{"award-number":["CA15135"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["COST-1103"],"award-info":[{"award-number":["COST-1103"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003339","name":"Consejo Superior de Investigaciones Cient\u00edficas","doi-asserted-by":"publisher","award":["SAF2006-08764-C02-01SAF2009-07271"],"award-info":[{"award-number":["SAF2006-08764-C02-01SAF2009-07271"]}],"id":[{"id":"10.13039\/501100003339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003339","name":"Consejo Superior de Investigaciones Cient\u00edficas","doi-asserted-by":"publisher","award":["SAF2012-33304"],"award-info":[{"award-number":["SAF2012-33304"]}],"id":[{"id":"10.13039\/501100003339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003339","name":"Consejo Superior de Investigaciones Cient\u00edficas","doi-asserted-by":"publisher","award":["SAF2015-65586-R"],"award-info":[{"award-number":["SAF2015-65586-R"]}],"id":[{"id":"10.13039\/501100003339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.bmcl.2019.126880","type":"journal-article","created":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T02:43:50Z","timestamp":1575859430000},"page":"126880","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Propargylamine-derived multi-target directed ligands for Alzheimer\u2019s disease therapy"],"prefix":"10.1016","volume":"30","author":[{"given":"Maria","family":"do Carmo Carreiras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lhassane","family":"Ismaili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Marco-Contelles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2019.126880_b0005","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/clpt.2010.165","article-title":"The development of new therapeutics for Alzheimer\u2019s disease","volume":"88","author":"Carter","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bmcl.2019.126880_b0010","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1517\/13543784.9.4.899","article-title":"Ongoing trials in Alzheimer\u2019s disease","volume":"9","author":"Sramek","year":"2000","journal-title":"Exp Opin Invest Drugs"},{"key":"10.1016\/j.bmcl.2019.126880_b0015","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2174\/156720501209151019111448","article-title":"Socio-economic aspects of Alzheimer\u2019s disease","volume":"12","author":"Maresova","year":"2015","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.bmcl.2019.126880_b0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0210958","article-title":"Predictions of Alzheimer\u2019s disease treatment and care costs in European countries","volume":"14","author":"Cimler","year":"2019","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bmcl.2019.126880_b0025","first-page":"14","article-title":"Neurotransmitter measures in the cerebrospinal fluid of patients with Alzheimer\u2019s disease: a review","volume":"27","author":"Strac","year":"2015","journal-title":"Psychiat Danub"},{"key":"10.1016\/j.bmcl.2019.126880_b0030","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1021\/acschemneuro.8b00069","article-title":"Alzheimer\u2019s disease, the \u201cone-molecule, one-target\u201d paradigm, and the multitarget directed ligand approach","volume":"9","author":"Oset-Gasque","year":"2018","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.bmcl.2019.126880_b0035","doi-asserted-by":"crossref","first-page":"697","DOI":"10.2147\/CIA.S129145","article-title":"Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson\u2019s disease dementia","volume":"12","author":"Kandiah","year":"2017","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.bmcl.2019.126880_b0040","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ejmech.2017.03.062","article-title":"Recent progress in the identification of selective butyrylcholinesterase inhibitors for Alzheimer\u2019s disease","volume":"132","author":"Li","year":"2017","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2019.126880_b0045","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.3390\/molecules24142568","article-title":"Discovery of new selective butyrylcholinesterase (BChE) inhibitors with anti-A\u03b2 aggregation activity: structure-based virtual screening, hit optimization and biological evaluation","volume":"24","author":"Jiang","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.bmcl.2019.126880_b0050","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bbr.2011.07.035","article-title":"Butyrylcholinesterase inhibitors ameliorate cognitive dysfunction induced by amyloid-\u03b2 peptide in mice","volume":"225","author":"Furukawa-Hibi","year":"2011","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.bmcl.2019.126880_b0055","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.2174\/15680266113139990135","article-title":"The multifactorial nature of Alzheimer\u2019s disease for developing potential therapeutics","volume":"13","author":"Carreiras","year":"2013","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.bmcl.2019.126880_b0060","first-page":"18","article-title":"The central role of biometals maintains oxidative balance in the context of metabolic and neurodegenerative disorders","author":"Pokusa","year":"2017","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.bmcl.2019.126880_b0065","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00441-004-0976-5","article-title":"Redox imbalance","volume":"318","author":"Berg","year":"2004","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.bmcl.2019.126880_b0070","doi-asserted-by":"crossref","first-page":"325","DOI":"10.5607\/en.2015.24.4.325","article-title":"The role of oxidative stress in neurodegenerative diseases","volume":"24","author":"Kim","year":"2015","journal-title":"Exp Neurobiol"},{"key":"10.1016\/j.bmcl.2019.126880_b0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/610813","article-title":"Interrelation of oxidative stress and inflammation in neurodegenerative disease: role of TNF","volume":"2015","author":"Fischer","year":"2015","journal-title":"Oxid Med Cell Longevity"},{"key":"10.1016\/j.bmcl.2019.126880_b0080","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1111\/j.1582-4934.2012.01585.x","article-title":"Blood markers of oxidative stress in Alzheimer\u2019s disease","volume":"16","author":"Skoumalov\u00e1","year":"2012","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.bmcl.2019.126880_b0085","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3389\/fnmol.2017.00339","article-title":"Biometal dyshomeostasis and toxic metal accumulations in the development of Alzheimer\u2019s disease","volume":"10","author":"Li","year":"2017","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.bmcl.2019.126880_b0090","doi-asserted-by":"crossref","first-page":"6727","DOI":"10.1039\/C4CS00138A","article-title":"Biological metals and metal-targeting compounds in major neurodegenerative diseases","volume":"43","author":"Barnham","year":"2014","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.bmcl.2019.126880_b0095","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.nbd.2015.08.007","article-title":"The relationship between iron dyshomeostasis and amyloidogenesis in Alzheime\u0155s disease: two sides of the same coin","volume":"81","author":"Peters","year":"2015","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.bmcl.2019.126880_b0100","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.bcp.2014.01.032","article-title":"Alzheimer\u2019s disease therapeutics targeted to the control of amyloid precursor protein translation: maintenance of brain iron homeostasis","volume":"88","author":"Bandyopadhyay","year":"2014","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bmcl.2019.126880_b0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147488","article-title":"Effect of copper and zinc on the single molecule self-affinity of Alzheime\u0155s amyloid \u03b2 peptides","volume":"11","author":"Hane","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bmcl.2019.126880_b0110","doi-asserted-by":"crossref","first-page":"6625","DOI":"10.1021\/ja210588m","article-title":"Bifunctional compounds for controlling metal-mediated aggregation of the A\u03b242 peptide","volume":"134","author":"Sharma","year":"2012","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bmcl.2019.126880_b0115","doi-asserted-by":"crossref","first-page":"20555","DOI":"10.1074\/jbc.M112.344036","article-title":"Zn2+-A\u03b240 complexes form metastable quasi-spherical oligomers that are cytotoxic to cultured hippocampal neurons","volume":"287","author":"Solomonov","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmcl.2019.126880_b0120","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3389\/fnins.2018.00441","article-title":"Contribution of Tau pathology to mitochondrial impairment in neurodegeneration","volume":"12","author":"P\u00e9rez","year":"2018","journal-title":"Front Neurosci"},{"key":"10.1016\/j.bmcl.2019.126880_b0125","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1111\/j.1471-4159.2009.05901.x","article-title":"Chronic copper exposure exacerbates both amyloid and tau pathology and selectively dysregulates cdk5 in a mouse model of AD","volume":"108","author":"Kitazawa","year":"2009","journal-title":"J Neurochem"},{"key":"10.1016\/j.bmcl.2019.126880_b0130","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.celrep.2014.06.047","article-title":"Zinc binding directly regulates Tau toxicity independent of Tau hyperphosphorylation","volume":"8","author":"Huang","year":"2014","journal-title":"Cell Rep"},{"key":"10.1016\/j.bmcl.2019.126880_b0135","doi-asserted-by":"crossref","first-page":"34648","DOI":"10.1074\/jbc.M109.058883","article-title":"Low micromolar zinc accelerates the fibrillization of human Tau via bridging of Cys-291 and Cys-322","volume":"284","author":"Mo","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmcl.2019.126880_b0140","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.2174\/156802612805219978","article-title":"Monoamine oxidases: The biochemistry of the proteins as targets in medicinal chemistry and drug discovery","volume":"12","author":"Ramsay","year":"2012","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.bmcl.2019.126880_b0145","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3389\/fphar.2016.00340","article-title":"Inhibitors of MAO A and MAO B in psychiatry and neurology","volume":"7","author":"Finberg","year":"2016","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.bmcl.2019.126880_b0150","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3389\/fnins.2018.00419","volume":"12","author":"Quartey","year":"2018","journal-title":"Front Neurosci"},{"key":"10.1016\/j.bmcl.2019.126880_b0155","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00702-003-0828-6","article-title":"Early and persistent alterations in prefrontal cortex MAO A and B in Alzheimer\u2019s disease","volume":"110","author":"Kennedy","year":"2003","journal-title":"J Neural Transm"},{"key":"10.1016\/j.bmcl.2019.126880_b0160","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1007\/s00702-017-1832-6","article-title":"Type A and B monoamine oxidases distinctly modulate signal transduction pathway and gene expression to regulate brain function and survival of neurons","volume":"125","author":"Naoi","year":"2018","journal-title":"J Neural Transm"},{"key":"10.1016\/j.bmcl.2019.126880_b0165","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1471-2202-8-73","article-title":"Calcium-sensitive regulation of monoamine oxidase A contributes to the production of peroxyradicals in hippocampal cultures: implications for Alzheimer disease-related pathology","volume":"8","author":"Cao","year":"2007","journal-title":"BMC Neurosci"},{"key":"10.1016\/j.bmcl.2019.126880_b0170","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.3892\/mmr.2014.2040","article-title":"Monoamine oxidase inhibitors: Promising therapeutic agents for Alzheimer\u2019s disease (Review)","volume":"9","author":"Cai","year":"2014","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.bmcl.2019.126880_b0175","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13195-017-0279-1","article-title":"Monoamine oxidase B is elevated in Alzheimer disease neurons, is associated with \u03b3-secretase and regulates neuronal amyloid \u03b2-peptide levels","volume":"9","author":"Schedin-Weiss","year":"2017","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.bmcl.2019.126880_b0180","doi-asserted-by":"crossref","first-page":"6264","DOI":"10.1021\/jm060441e","article-title":"Impact of species-dependent differences on screening, design, and development of MAO B inhibitors","volume":"49","author":"Novaroli","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2019.126880_b0185","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000116655","article-title":"Effects of a MAO B inhibitor in the treatment of Alzheimer disease","volume":"31","author":"Mangoni","year":"1991","journal-title":"Eur Neurol"},{"key":"10.1016\/j.bmcl.2019.126880_b0190","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0022-3565(24)38924-4","article-title":"Multiple central nervous system targets for eliciting beneficial effects on memory and cognition","volume":"295","author":"Buccafusco","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bmcl.2019.126880_b0195","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0166-4328(00)00261-8","article-title":"Alzheimer\u2019s disease: more than a \u201ccholinergic disorder\u201d- evidence that cholinergic-monoaminergic interactions contribute to EEG slowing and dementia","volume":"115","author":"Dringenberg","year":"2000","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.bmcl.2019.126880_b0200","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.pneurobio.2016.04.001","article-title":"Monoaminergic neuropathology in Alzheimer\u2019s disease","volume":"151","author":"Simic","year":"2017","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.bmcl.2019.126880_b0205","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.neubiorev.2013.05.008","article-title":"Ascending monoaminergic systems alterations in Alzheimer\u2019s disease. Translating basic science into clinical care","volume":"37","author":"Trillo","year":"2013","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.bmcl.2019.126880_b0210","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3389\/fnins.2016.00541","article-title":"Monoaminergic and histaminergic strategies and treatments in brain diseases","volume":"10","author":"Di Giovanni","year":"2016","journal-title":"Front Neurosci"},{"key":"10.1016\/j.bmcl.2019.126880_b0215","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0197-4580(00)00100-7","article-title":"Monoamine oxidase-B inhibitors in the treatment of Alzheimers disease","volume":"21","author":"Thomas","year":"2000","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.bmcl.2019.126880_b0220","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1111\/bph.13318","article-title":"Neuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and \u03b2-amyloid in ageing and Alzheimer\u2019s disease","volume":"173","author":"Weinreb","year":"2016","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bmcl.2019.126880_b0225","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3233\/JAD-2010-100150","article-title":"Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-\u03b2 protein precursor: Involvement of MAPK and PKC activation","volume":"21","author":"Bar-Am","year":"2010","journal-title":"J Alzheimer\u2019s Dis"},{"key":"10.1016\/j.bmcl.2019.126880_b0230","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1096\/fj.03-0078fje","article-title":"The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives for MAPK-dependent amyloid precursor protein processing","volume":"17","author":"Yogev-Falach","year":"2003","journal-title":"FASEB J"},{"key":"10.1016\/j.bmcl.2019.126880_b0235","first-page":"121","article-title":"Neuroprotection by propargylamines in Parkinson\u2019s disease: intracellular mechanism underlying the anti-apoptotic function and search for clinic markers","volume":"72","author":"Naoi","year":"2007","journal-title":"J Neural Transm"},{"key":"10.1016\/j.bmcl.2019.126880_b0240","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2174\/156720506779025288","article-title":"The path from anti Parkinson drug Selegiline and Rasagiline to multifunctional neuroprotective anti Alzheimer drugs Ladostigil and M30","volume":"3","author":"Youdim","year":"2006","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.bmcl.2019.126880_b0245","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/j.1471-4159.2007.04777.x","article-title":"Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro","volume":"103","author":"Bar-Am","year":"2007","journal-title":"J Neurochem"},{"key":"10.1016\/j.bmcl.2019.126880_b0250","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s00702-012-0948-y","article-title":"Propargylamine-derived multitarget-directed ligands: fighting Alzheime\u0155s disease with monoamine oxidase inhibitors","volume":"120","author":"Bolea","year":"2013","journal-title":"J Neural Transm"},{"key":"10.1016\/j.bmcl.2019.126880_b0255","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0892-0362(02)00221-0","article-title":"Neuroprotection by propargylamines in Parkinson\u2019s disease. Suppression of apoptosis and induction of prosurvival genes","volume":"24","author":"Maruyama","year":"2002","journal-title":"Neurotoxicol Teratol"},{"key":"10.1016\/j.bmcl.2019.126880_b0260","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00702-015-1395-3","article-title":"Neuroprotective and neurorestorative potential of propargylamine derivatives in ageing: focus on mitochondrial targets","volume":"123","author":"Bar-Am","year":"2016","journal-title":"J Neural Transm"},{"key":"10.1016\/j.bmcl.2019.126880_b0265","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/jnr.20350","article-title":"Rasagiline: Neurodegeneration, neuroprotection, and mitochondrial permeability transition","volume":"79","author":"Youdim","year":"2005","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.bmcl.2019.126880_b0270","first-page":"348","article-title":"Novel neuroprotective mechanism of action of rasagiline is associated with its propargyl moiety: interaction of Bcl-2 family members with PKC pathway","volume":"1053","author":"Weinreb","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.bmcl.2019.126880_b0275","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.brainresrev.2004.12.027","article-title":"Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives","volume":"48","author":"Mandel","year":"2005","journal-title":"Brain Res Rev"},{"key":"10.1016\/j.bmcl.2019.126880_b0280","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1096\/fj.05-3794fje","article-title":"Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine","volume":"19","author":"Bar-Am","year":"2005","journal-title":"FASEB J"},{"key":"10.1016\/j.bmcl.2019.126880_b0285","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.pharmthera.2014.02.010","article-title":"Update on the pharmacology of selective inhibitors of MAO A and MAO B: focus on modulation of CNS monoamine neurotransmitter release","volume":"143","author":"Finberg","year":"2014","journal-title":"Pharmcol Ther"},{"key":"10.1016\/j.bmcl.2019.126880_b0290","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/B978-0-12-386467-3.00009-1","article-title":"Selective inhibitors of monoamine oxidase type B and the \u201ccheese effect\u201d","volume":"100","author":"Finberg","year":"2011","journal-title":"Int Rev Neurobiol"},{"key":"10.1016\/j.bmcl.2019.126880_b0295","first-page":"31","article-title":"Safinamide: an add-on treatment for managing Parkinson\u2019s disease","volume":"10","author":"M\u00fcller","year":"2018","journal-title":"Clin Pharmacol"},{"key":"10.1016\/j.bmcl.2019.126880_b0300","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1096\/fj.05-4910fje","article-title":"A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing","volume":"20","author":"Yogev-Falach","year":"2006","journal-title":"FASEB J"},{"key":"10.1016\/j.bmcl.2019.126880_b0305","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0304-3940(03)00211-8","article-title":"Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor","volume":"341","author":"Maruyama","year":"2003","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.bmcl.2019.126880_b0310","first-page":"157","article-title":"TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer\u2019s disease","volume":"60","author":"Weinstock","year":"2000","journal-title":"J Neural Transm"},{"key":"10.1016\/j.bmcl.2019.126880_b0315","doi-asserted-by":"crossref","first-page":"5884","DOI":"10.1016\/j.bmc.2012.07.045","article-title":"O-Hydroxyl- or o-amino benzylamine-tacrine hybrids: Multifunctional biometals chelators, antioxidants, and inhibitors of cholinesterase activity, and amyloid-\u03b2 aggregation","volume":"20","author":"Mao","year":"2012","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmcl.2019.126880_b0320","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.ejmech.2013.01.039","article-title":"A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer\u2019s disease","volume":"62","author":"Lu","year":"2013","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2019.126880_b0325","doi-asserted-by":"crossref","first-page":"995","DOI":"10.3109\/14756366.2014.1003212","article-title":"Tacrine-propargylamine derivatives with improved acetylcholinesterase inhibitory activity and lower hepatotoxicity as a potential lead compound for the treatment of Alzheimer\u2019s disease","volume":"30","author":"Mao","year":"2015","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10.1016\/j.bmcl.2019.126880_b0330","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/cbdd.12633","article-title":"New tacrine hybrids with natural-based cysteine derivatives as multitargeted drugs for potential treatment of Alzheimer\u2019s disease","volume":"87","author":"Keri","year":"2016","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.bmcl.2019.126880_b0335","doi-asserted-by":"crossref","first-page":"53519","DOI":"10.1039\/C6RA03455A","article-title":"Tacrine-allyl\/propargylcysteine-benzothiazole trihybrids as potential anti-Alzheimer\u2019s drug candidates","volume":"6","author":"Hiremathad","year":"2016","journal-title":"RSC Adv"},{"key":"10.1016\/j.bmcl.2019.126880_b0340","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/S0040-4039(00)00036-8","article-title":"A facile synthesis of bis-tacrines isosteres","volume":"41","author":"Hu","year":"2000","journal-title":"Tetrahedron Lett"},{"key":"10.1016\/j.bmcl.2019.126880_b0345","doi-asserted-by":"crossref","first-page":"6058","DOI":"10.1039\/c3dt50406a","article-title":"Multifunctional iron-chelators with protective roles against neurodegenerative diseases","volume":"42","author":"Nunes","year":"2013","journal-title":"Dalton Trans"},{"key":"10.1016\/j.bmcl.2019.126880_b0350","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jinorgbio.2015.06.008","article-title":"Copper (II) complexation of tacrine hybrids with potential anti-neurodegenerative roles","volume":"151","author":"Quintanova","year":"2015","journal-title":"J Inorg Biochem"},{"key":"10.1016\/j.bmcl.2019.126880_b0355","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.1016\/j.bmc.2016.06.045","article-title":"Design, synthesis and biological evaluation of N-methyl-N-[(1,2,3-triazol-4-yl)alkyl]propargylamines as novel monoamine oxidase B inhibitors","volume":"24","author":"Di Pietro","year":"2016","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmcl.2019.126880_b0360","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3390\/molecules21030362","article-title":"Searching for multi-targeting neurotherapeutics against Alzheimer\u2019s: Discovery of potent AChE-MAO B inhibitors through the decoration of the 2H-Chromen-2-one structural motif","volume":"21","author":"Pisani","year":"2016","journal-title":"Molecules"},{"key":"10.1016\/j.bmcl.2019.126880_b0365","doi-asserted-by":"crossref","first-page":"8148","DOI":"10.1021\/jm0506266","article-title":"Binding of rasagiline-related inhibitors to human monoamine oxidases: A kinetic and crystallographic analysis","volume":"48","author":"Binda","year":"2005","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2019.126880_b0370","doi-asserted-by":"crossref","first-page":"609","DOI":"10.4155\/fmc.15.12","article-title":"Propargylamine as functional moiety in the design of multifunctional drugs for neurodegenerative disorders: MAO inhibition and beyond","volume":"7","author":"Zindo","year":"2015","journal-title":"Future Med Chem"},{"key":"10.1016\/j.bmcl.2019.126880_b0375","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.bmc.2016.11.032","article-title":"N-propargylpiperidines with naphthalene-2-carboxamide or naphthalene-2-sulfonamide moieties: potential multifunctional anti-Alzheimer\u2019s agentes","volume":"25","author":"Kosak","year":"2017","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmcl.2019.126880_b0380","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/j.tetlet.2014.02.034","article-title":"Straightforward synthesis of orthogonally protected piperidin-3-ylmethanamine and piperidin-4-ylmethanamine derivatives","volume":"55","author":"Kosak","year":"2014","journal-title":"Tetrahedron Lett"},{"key":"10.1016\/j.bmcl.2019.126880_b0385","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/sj.bjp.0702600","article-title":"Relevance of benzyloxy group in 2-indolyl methylamines in the selective MAO-B inhibition","volume":"127","author":"P\u00e9rez","year":"1999","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bmcl.2019.126880_b0390","doi-asserted-by":"crossref","first-page":"8251","DOI":"10.1021\/jm200853t","volume":"54","author":"Bolea","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2019.126880_b0395","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3389\/fnins.2016.00294","volume":"10","author":"Marco-Contelles","year":"2016","journal-title":"Front Neurosci"},{"key":"10.1016\/j.bmcl.2019.126880_b0400","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.bbapap.2014.03.006","article-title":"Kinetic and structural analysis of the irreversible inhibition of human monoamine oxidases by ASS234, a multi-target compound designed for use in Alzheimer\u2019s disease","volume":"1844","author":"Esteban","year":"2014","journal-title":"Biochim Biophy Acta"},{"key":"10.1016\/j.bmcl.2019.126880_b0405","doi-asserted-by":"crossref","first-page":"797","DOI":"10.2174\/15672050113109990151","article-title":"Multipotent, permeable drug ASS234 inhibits A\u03b2 aggregation, possesses antioxidant properties and protects from A\u03b2-induced apoptosis in vitro","volume":"10","author":"Bolea","year":"2013","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.bmcl.2019.126880_b0410","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/cns.12590","article-title":"Upregulation of antioxidant enzymes by ASS234, a multitarget directed propargylamine for Alzheimer\u2019s disease therapy","volume":"22","author":"Ramos","year":"2016","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.bmcl.2019.126880_b0415","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1503\/jpn.150209","article-title":"The proof-of-concept of ASS234: Peripherally administered ASS234 enters the central nervous system and reduces pathology in a male mouse model of Alzheimer disease","volume":"42","author":"Serrano","year":"2017","journal-title":"J Psychiatry Neurosci"},{"key":"10.1016\/j.bmcl.2019.126880_b0420","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2174\/13816128113199990026","article-title":"Effects of novel monoamine oxidases and cholinesterases targeting compounds on brain neurotransmitters and behavior in rat model of vascular dementia","volume":"20","author":"Stasiak","year":"2014","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.bmcl.2019.126880_b0425","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/jphp.12697","article-title":"In-vitro and in-vivo evaluation of the modulatory effects of the multitarget compound ASS234 on the monoaminergic system","volume":"69","author":"Esteban","year":"2017","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.bmcl.2019.126880_b0430","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.pharmthera.2008.01.004","article-title":"The Wnt signaling pathway: Aging gracefully as a protectionist?","volume":"118","author":"Maiese","year":"2008","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bmcl.2019.126880_b0435","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/cns.12269","article-title":"Wnt signaling pathway, a potential target for Alzheimer\u2019s disease treatment, is activated by a novel multitarget compound ASS234","volume":"20","author":"Del Pino","year":"2014","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.bmcl.2019.126880_b0440","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1523\/JNEUROSCI.0862-13.2014","article-title":"In vivo activation of Wnt signaling pathway enhances cognitive function of adult mice and reverses cognitive deficits in an Alzheimer\u2019s disease model","volume":"34","author":"Vargas","year":"2014","journal-title":"J Neurosci"},{"key":"10.1016\/j.bmcl.2019.126880_b0445","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1021\/acs.chemrestox.8b00192","article-title":"Modulation of heat shock response proteins by ASS234, targeted for neurodegenerative diseases therapy","volume":"31","author":"Ramos","year":"2018","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.bmcl.2019.126880_b0450","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1021\/acschemneuro.8b00203","article-title":"Neuroinflammation signaling modulated by ASS234, a multitarget small molecule for Alzheimer\u2019s disease therapy","volume":"9","author":"del Pino","year":"2018","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.bmcl.2019.126880_b0455","first-page":"1893","article-title":"Multipotent cholinesterase\/monoamine oxidase inhibitors for the treatment of Alzheimer\u2019s disease: design, synthesis, biochemical evaluation, ADMET, molecular modeling, and QSAR analysis of novel donepezil-pyridyl hybrids","volume":"8","author":"Bautista-Aguilera","year":"2014","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.bmcl.2019.126880_b0460","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejmech.2013.12.028","article-title":"Design, synthesis, pharmacological evaluation, QSAR analysis, molecular modeling and ADMET of novel donepezil-indolyl hybrids as multipotent cholinesterase\/monoamine oxidase inhibitors for the potential treatment of Alzheime\u0155s disease","volume":"75","author":"Bautista-Aguilera","year":"2014","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2019.126880_b0465","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ejmech.2014.04.078","article-title":"Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer\u2019s disease","volume":"80","author":"Wang","year":"2014","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2019.126880_b0470","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.ejmech.2015.10.001","article-title":"Donepezil-like multifunctional agents: Design, synthesis, molecular modeling and biological evaluation","volume":"121","author":"Wu","year":"2016","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2019.126880_b0475","doi-asserted-by":"crossref","first-page":"10455","DOI":"10.1021\/jm501501a","article-title":"N-Methyl-N-((1-methyl-5-(3-(1-(2-methylbenzyl)piperidin-4-yl)propoxy)-1H-indol-2-yl)methyl)prop-2-yn-1-amine, a new cholinesterase and monoamine oxidase dual inhibitor","volume":"57","author":"Bautista-Aguilera","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2019.126880_b0480","doi-asserted-by":"crossref","first-page":"6937","DOI":"10.1021\/acs.jmedchem.8b00848","article-title":"Contilisant, a tetratarget small molecule for Alzheimer\u2019s disease therapy combining cholinesterase, monoamine oxidase inhibition, and H3R antagonism with S1R agonism profile","volume":"61","author":"Bautista-Aguilera","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2019.126880_b0485","doi-asserted-by":"crossref","first-page":"12765","DOI":"10.1002\/anie.201706072","article-title":"Multitarget-Directed ligands combining cholinesterase and monoamine oxidase inhibition with histamine H3R antagonism for neurodegenerative diseases","volume":"56","author":"Bautista-Aguilera","year":"2017","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.bmcl.2019.126880_b0490","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1039\/C7MD00569E","article-title":"Design, synthesis and evaluation of indole derivatives as multifunctional agents against Alzheimer\u2019s disease","volume":"9","author":"Denya","year":"2018","journal-title":"Med Chem Commun"},{"key":"10.1016\/j.bmcl.2019.126880_b0495","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejmech.2014.04.039","article-title":"Polycyclic propargylamine and acetylene derivatives as multifunctional neuroprotective agents","volume":"80","author":"Zindo","year":"2014","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2019.126880_b0500","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejmech.2018.11.051","article-title":"Design, synthesis and evaluation of pentacycloundecane and hexacycloundecane propargylamine derivatives as multifunctional neuroprotective agents","volume":"163","author":"Zindo","year":"2019","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2019.126880_b0505","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.neuropharm.2016.06.013","article-title":"Design, synthesis and evaluation of novel dual monoamine-cholinesterase inhibitors as potential treatment for Alzheimer\u2019s disease","volume":"109","author":"Liu","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bmcl.2019.126880_b0510","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.neuropharm.2017.05.026","article-title":"The novel multitarget iron chelating and propargylamine drug M30 affects APP regulation and processing activities in Alzheimer\u2019s disease models","volume":"123","author":"Amit","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bmcl.2019.126880_b0515","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejmech.2017.08.025","article-title":"Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer\u2019s disease","volume":"143","author":"Xu","year":"2018","journal-title":"Eur J Med Chem"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X19308583?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X19308583?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:31:35Z","timestamp":1760772695000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X19308583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":103,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0960894X19308583"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2019.126880","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Propargylamine-derived multi-target directed ligands for Alzheimer\u2019s disease therapy","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2019.126880","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"126880"}}